Sensus Healthcare to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
09 Oktober 2023 - 2:00PM
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company
specializing in highly effective, non-invasive, minimally-invasive
and cost-effective treatments for oncological and non-oncological
conditions, announces that management will deliver a company
presentation and hold investor meetings at the Roth MKM 2023
Healthcare Opportunities Conference being held October 12, 2023 in
New York City. Sensus management will also participate in the 43rd
Annual Fall Clinical Dermatology Conference being held October
19-22, 2023 at the Wynn Hotel in Las Vegas.
Joe Sardano, chairman and chief executive
officer of Sensus Healthcare, will deliver a 10-minute presentation
at 11:15 a.m. Eastern time at the Yale Club. The presentation will
not be webcast. Management will also be available for one-on-one
meetings at the conference. To request a meeting with Sensus
Healthcare management, please contact your Roth MKM representative
or Kim Golodetz at LHA Investor Relations at
kgolodetz@lhai.com.
Sensus will showcase its advancements in
superficial radiotherapy at the 43rd Annual Fall Clinical
Dermatology Conference, while demonstrating its SRT-100™,
SRT-100+™, SRT-100 Vision™ with IG-SRT, using the latest ultrasound
technology for accurate visualization of the dermis, and Sentinel™,
its proprietary IT Solutions product.
Sensus Healthcare's devices utilize the
Multi-Dimensional Superficial Radiotherapy platform, which provides
an alternative low-energy X-ray treatment for various types of
non-melanoma skin cancer and keloids. Designed to deliver effective
and safe radiotherapy, SRT offers patients a non-surgical, painless
and cosmetically appealing treatment option. By enabling seamless
integration with existing healthcare systems, Sensus Healthcare's
solutions ensure enhanced flexibility and convenience for
healthcare providers.
Fall Clinical participants are invited to visit
Sensus Healthcare at the Wynn Hotel to witness live product
demonstrations and interact with the company's knowledgeable
representatives. To schedule an appointment or for more information
about Sensus Healthcare's participation, please contact Sensus
Healthcare by visiting www.sensushealthcare.com.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in
the development and delivery of non-invasive treatments for skin
cancer and keloids. Leveraging its cutting-edge superficial
radiotherapy (SRT) technology, the company provides healthcare
providers with a highly effective, patient-centric treatment
platform. With a dedication to driving innovation in radiation
oncology, Sensus Healthcare offers solutions that are safe,
precise, and adaptable to a variety of clinical settings. For more
information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are,
or may be deemed, ''forward-looking statements.'' In some cases,
these statements can be identified by the use of forward-looking
terminology such as "believes," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should," “approximately,” "potential" or negative or other
variations of those terms or comparable terminology, although not
all forward-looking statements contain these words.
Forward-looking statements involve risks and
uncertainties because they relate to events, developments, and
circumstances relating to Sensus, our industry, and/or general
economic or other conditions that may or may not occur in the
future or may occur on longer or shorter timelines or to a greater
or lesser degree than anticipated. Although we believe that we have
a reasonable basis for each forward-looking statement contained in
this press release, forward-looking statements are not guarantees
of future performance, and our actual results of operations,
financial condition and liquidity, and the development of the
industry in which we operate may differ materially from the forward
looking statements contained in this press release, as a result of
the following factors, among others: our ability to return to
profitability; our ability to sell the number of SRT units we
anticipate for the balance of 2023; the possibility that
inflationary pressures continue to impact our sales; our ability to
obtain and maintain the intellectual property needed to adequately
protect our products, and our ability to avoid infringing or
otherwise violating the intellectual property rights of third
parties; the level and availability of government and/or third
party payor reimbursement for clinical procedures using our
products, and the willingness of healthcare providers to purchase
our products if the level of reimbursement declines; the regulatory
requirements applicable to us and our competitors; our ability to
efficiently manage our manufacturing processes and costs; the risks
arising from doing business in China and other foreign countries;
legislation, regulation, or other governmental action that affects
our products, taxes, international trade regulation, or other
aspects of our business; concentration of our customers in the U.S.
and China, including the concentration of sales to one particular
customer in the U.S.; and other risks described from time to time
in our filings with the Securities and Exchange Commission,
including our Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q.
To date, we do not expect that the Russian
invasion of Ukraine and global geopolitical uncertainty have not
had any particular impact on our business, but we continue to
monitor developments and will address them in future disclosures,
if applicable.
In addition, even if future events,
developments, and circumstances are consistent with the
forward-looking statements contained in this press release, they
may not be predictive of results or developments in future periods.
Any forward-looking statements that we make in this press release
speak only as of the date of such statement, and we undertake no
obligation to update such statements to reflect events or
circumstances after the date of this press release, except as may
be required by applicable law. You should read carefully our
"Introductory Note Regarding Forward-Looking Information" and the
factors described in the "Risk Factors" section of our periodic
reports filed with the Securities and Exchange Commission to better
understand the risks and uncertainties inherent in our
business.
Contact: LHA Investor Relations
Kim Sutton Golodetz212-838-3777kgolodetz@lhai.com
# # #
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024